



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16.

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, February 10<sup>th</sup>, 2018

To  
The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai-400001.

Dear Sir/Ma'am,

**Sub:** Outcome of Board Meeting – Regulation 30.


**Ref:** Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at the meeting held on Saturday, 10<sup>th</sup> February, 2018 at 04:30 PM at the Corporate office of the Company, interalia considered and approved the following:

1. Un-Audited Financial Results for the quarter ended 31<sup>st</sup> December, 2017.
2. Limited Review Report for the quarter ended 31<sup>st</sup> December, 2017.
3. To maintain the Book of Accounts at the Corporate office of the Company located at 7-1-212/A/70, Plot No. 85, Shivbagh, Ameerpet, Hyderabad- 500016, Telangana.

Thanking You,  
for Vista Pharmaceuticals Limited

*Chalapathirao Venkata Naraparaju*



**Chalapathirao Venkata Naraparaju**  
**Wholetime Director**  
**DIN: 03270178**

*Encl: as above*



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana  
India Tel: 91-40-65581585, Fax : 91-40-23741585  
e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, February 10<sup>th</sup>, 2018

To  
The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai- 400001.

Dear Sir/Ma'am,

**Sub:** Financial Results for the quarter ended 31<sup>st</sup> December, 2017 – Regulation 33 (3) (a).


**Ref:** Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Saturday, 10<sup>th</sup> February, 2018 at 04.30 P.M. at the Corporate office of the Company, interalia, considered and approved the un-audited Financial Results for the quarter ended 31<sup>st</sup> December, 2017.

Copy of Un-audited Financial Results for the quarter ended 31<sup>st</sup> December, 2017, along with copy of Limited Review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,  
for Vista Pharmaceuticals Limited



**Chalapathirao Venkata Naraparaju**  
**Wholetime Director**  
**DIN: 03270178**



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585


e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

## Unaudited Financial Results for the Quarter ended 31, December 2017

(Rs. in lakhs)

PARTICULARS	Quarter Ended			Year To Date Nine Months Ended On		Financial year Ended
	3 Months Ended	Preceding 3 Months Ended	corresponding 3 Months ended in the Previous Year	Year To Date figures for the current Period ended	Year To Date figures for the Previous Year ended	Previous Year Ended
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.03.2017
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>(a) Revenue from Operations</b>	711.59	669.91	629.29	2,110.93	1,806.66	2,418.19
(b) Other Income	0.00	70.07	-	70.07	0.43	5.74
<b>Total Income ( a + b )</b>	<b>711.59</b>	<b>739.98</b>	<b>629.29</b>	<b>2,181.00</b>	<b>1,807.09</b>	<b>2,423.93</b>
<b>Expenses</b>						
(a) Cost of Materials Consumed	370.31	387.63	120.19	847.67	402.11	439.28
(b) Cost of Traded goods	-	-	302.62	333.33	844.80	1,170.99
(c) Changes in inventories of stock-in-trade	-	-	-	-	-	-
(d) Employee Benefits Expense	26.68	23.73	19.56	71.42	56.16	87.64
(e) Finance Costs	38.18	38.75	20.38	117.30	62.55	87.60
(f) Depreciation and amortisation expense	56.04	29.65	25.32	111.07	77.71	101.51
(g) Manufacturing & Other Expenses	148.49	169.58	100.07	481.90	260.87	414.66
<b>Total Expenses</b>	<b>639.70</b>	<b>649.34</b>	<b>588.14</b>	<b>1,962.69</b>	<b>1,704.20</b>	<b>2,301.68</b>
<b>Profit before tax</b>	<b>71.89</b>	<b>90.64</b>	<b>41.15</b>	<b>218.31</b>	<b>102.89</b>	<b>122.25</b>
<b>Tax Expenses</b>						
Current Tax	14.66	18.48	-	44.51	-	6.76
Deferred Tax	(2.22)	10.78	(2.31)	12.81	(6.94)	(9.26)
<b>Profit for the period / year</b>	<b>59.45</b>	<b>61.38</b>	<b>43.46</b>	<b>160.99</b>	<b>109.83</b>	<b>124.75</b>
<b>Other Comprehensive Income</b>						
Items that will not be reclassified to Profit and Loss	-	-	-	-	-	-
-Remeasurement gains/(losses) on defined benefit plan	-	-	-	-	-	-
-Tax on above	-	-	-	-	-	-
Other Comprehensive Income / (Loss)	-	-	-	-	-	-
<b>Total Comprehensive Income for the period / year (after tax )</b>	<b>59.45</b>	<b>61.38</b>	<b>43.46</b>	<b>160.99</b>	<b>109.83</b>	<b>124.75</b>
Paid-up equity share capital (Face value Rs.2/- per share)	572.94	572.94	500.00	572.94	500.00	531.43
Other Equity	-	-	-	-	-	-
<b>Earnings per equity share of Rs.2/- each</b>						
Basic (Not Annualised.)	0.21	0.21	0.17	0.56	0.44	0.47
Diluted (Not Annualised.)	0.21	0.21	0.17	0.56	0.44	0.47

*Handwritten signature*





# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana  
India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

## Notes :-

1.The above financial results for the quarter and Nine months ended December 31, 2017 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on February 10, 2018. The financial results for the Quarter and Nine Months Ended December 31, 2017 has been subjected to limited review by the company's Statutory Auditors

2.The company has adopted Indian Accounting Standards(Ind AS) prescribed under section 133 of the Companies Act , 2013 read with the relevant rules issued there under. The date of Transition to Ind AS is April 01, 2016 and accordingly these unaudited financial results have been prepared in accordance with the recognition and measurements principles laid down in Ind AS 34 'Interim Financial Reporting" and the other accounting principles generally accepted in India .

3.Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter and half year ended 31.12.2016

Particulars	Quarter Ended 31.12.2016 (Unaudited)	Nine Months ended 31.12.2016 (Unaudited)
Net profit under previous GAAP	42.02	102.56
a)Impact on account of current & deferred taxes	2.31	6.94
b)Impairment of trade receivables due to expected credit loss & probability of default	-0.87	0.33
c) Impact of measurement of investments at fair value	-	-
Net profit under Ind AS	43.46	109.83


4.The financial results and other financial information for the Quarter and Nine Months ended 31 December , 2016 has been compiled by the management as per Ind AS , after exercising necessary due diligence , to ensure that the financial results provided true and fair view of the results in accordance with Ind AS. This information has not been subject to any limited review or audit.

5. There is possibility that these Quarterly financial results may require adjustment before constituting the final Ind AS financial Statements as of and for the year ending March 31st , 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of 1 or more optional exemptions from full retrospective application as permitted under Ind AS 101

6. Company filed an ANDA (Abbreviated New Drug Application) in September 2017 for a complex cardiac drug with limited competition. This ANDA has been filed with a USA based financial partner, This ANDA has a market size of 195 million US Dollars. The Company chalked out a strategy to develop niche and complex generics with limited competition.

7. The Company operates in a single segment and the results pertain to a single segment.

N.V.Chalapathi Rao  
Director  
Din No.03270178



Place : Hyderabad  
Date: 10.02.2018



# V KISHORE KUMAR & ASSOCIATES

Chartered Accountants

## Limited Review Report

**Review Report To  
The Board of Directors  
Vista Pharmaceuticals Limited**

1. We have reviewed the accompanying statement of unaudited financial results of VISTA PHARMACEUTICALS LIMITED ('the company'), for the quarter and year to date from April 01, 2017 to December 31, 2017 ('the statement') being submitted by the company pursuant to the requirement of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the standard on review Engagement (SRE) 2410, 'Review of Interim financial information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquire of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting Standards i.e. Indian Accounting Standards ('Ins AS') prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V Kishore Kumar & Associates  
Chartered Accountants  
Firm Registration No: 013975S



V. Kishore Kumar  
Partner  
Membership No.:222865

Place: Hyderabad  
Date: 10<sup>th</sup> February 2018